A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?

Veronica Villani, Alessandra Fabi, Antonio Tanzilli, Francesco Pasqualetti, Giuseppe Lombardi, Antonello Vidiri, Alessandra Gonnelli, Alessandro Molinari, Martina Cantarella, Luisa Bellu, Irene Terrenato, Mariantonia Carosi, Marta Maschio, Stefano Maria Telera, Carmine Maria Carapella, Francesco Cognetti, Fabiola Paiar, Vittorina Zagonel, Andrea Pace

Research output: Contribution to journalArticle


Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.

Original languageEnglish
Pages (from-to)1717-1727
Number of pages11
JournalFuture Oncology
Issue number15
Publication statusPublished - May 2019



  • bevacizumab
  • clinical benefit
  • glioma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this